Indegene has announced that global life sciences leader Jill DeSimone and Neeraj Bharadwaj, a renowned private equity leader, have joined Indegene’s Board of Directors.
Jill DeSimone offers more than 40 years of life sciences leadership, with proven expertise in scaling large commercial and medical teams. She held top roles at major biopharma firms, including President of U.S. Oncology at Merck, where she drove global product franchises and spearheaded Keytruda’s launch—Merck’s pioneering oncology blockbuster. Her background also includes key positions at Teva and Bristol Myers Squibb, and she now serves on the boards of various public and private biotech companies, delivering strategic depth to Indegene.
Neeraj Bharadwaj brings deep expertise in private equity, capital allocation, and driving portfolio value. As a Senior Advisor at Carlyle Asia, he previously led growth investing at Accel Partners in India and held key roles at Apax Partners. He has partnered with boards and executives to fuel disciplined expansion, acquisitions, and long-term value in healthcare and tech-enabled services.
Manish Gupta, Chairman and CEO of Indegene, stated: “Strong corporate governance remains core to Indegene’s DNA. Jill and Neeraj join our board as esteemed leaders whose expertise mirrors our strategic priorities and operating model. Their insights will bolster governance and drive enduring value for stakeholders.”
